Abstract
Inflammatory bowel disease (IBD) is a group of inflammatory syndromes for the gastro-intestinal tract with the symptoms of abdominal pain, vomiting, diarrhea and rectal bleeding. Surgical and medical treatments are the principle therapies for IBD. However, inflammation often recurs at the resection site by surgical treatment. Furthermore, refers to the inflammatory area may occur in any position of the intestinal system, it’s difficult to release the drug at the specific targets. To deal with this problem, we had designed a foaming system via suppository delivery. The produced CO2 gas gave rise to create drug bubbles to extent the contact area between drug and bowel wall, and lead to increase drug diffusion in the intestinal tract. In recent studies, H2S was reported to mitigate inflammation by down-regulation of some pre-inflammatory genes, and was used in treating several kinds of inflammation. In this research, the hydrophobic H2S precursor diallyl trisulfide (DATS) was applied with the foaming system for IBD treatment. In the in vitro studies, it shows that the better DATS diffusion, the data also showed better cell utilization ability for the foaming group, compared to the w/o foaming group that cause a better anti-inflammation effects. In the in vivo studies of rat IBD model, it shows that the better recovery was observed for the foaming group than the no treatment and w/o foaming group by both the results of disease index record and histological H&E stain, along with a better down-regulation of some pre-inflammatory cytokines. These results validate our foaming system is benefit for DATS diffusion and cell utilization, which helps to anti-inflammatory and leads to good recovery of IBD.